TY - JOUR T1 - Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2020-000952 VL - 8 IS - 2 SP - e000952 AU - Ernesto Rossi AU - Giovanni Schinzari AU - Giampaolo Tortora Y1 - 2020/07/01 UR - http://jitc.bmj.com/content/8/2/e000952.abstract N2 - Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy. ER -